At 8.8% CAGR, the Middle East & Africa Brain Implants Market is Projected to be Worth US$ 449.09 million by 2030, Says Business Market Insights

According to Business Market Insights research, the Middle East & Africa brain implants market was valued at US$ 228.37 million in 2022 and is expected to reach US$ 449.09 million by 2030, registering a CAGR of 8.8% from 2022 to 2030. Surging prevalence of neurological disorders with increasing geriatric population and rising number of spinal cord injuries are among the critical factors attributed to the Middle East & Africa brain implants market expansion.

With age, elderly people are likely to develop neurological disorders that impact their mobility. Alzheimer's disease, epilepsy, Parkinson's disease (PD), and dystonia are among the most common neurological disorders affecting the geriatric population. According to an article titled "Alzheimer's disease: Can deep brain stimulation help alleviate symptoms" published in April 2023, ~32 million people worldwide have Alzheimer's disease. According to the World Health Organization (WHO) stats released in February 2022, approximately 50 million people suffer from epilepsy, which is one of the most common neurological diseases worldwide. The increasing incidence of neurological diseases, coupled with the growing geriatric population, drives the demand for brain implants to treat and manage the disease. The deep brain stimulation (DBS) technique is used to treat epilepsy cases due to the low therapeutic response exhibited by the patient's body to medication during seizures and reduced success rates associated with surgeries. Thus, neural implants such as DBS and vagus nerve stimulation are increasingly being used to treat patients with PD and other neurological conditions.

On the contrary, high cost associated with brain implant devices and procedures hampers the growth Middle East & Africa brain implants market.

Based on treatment, the Middle East & Africa brain implants market is classified into deep brain stimulation, spinal cord stimulation, vagus nerve stimulator, invasive and non-invasive brain-computer interface, responsive neurostimulation for seizures, auditory brainstem implant, and ophthalmic aid/implant. The spinal cord stimulation segment held 37.5% share of the Middle East & Africa brain implants market in 2022, amassing US$ 85.57 million. It is projected to garner US$ 115.04 million by 2030 to expand at 3.8% CAGR during 2022-2030. Further, the auditory brainstem implant segment is bifurcated into retrocochlear hearing impairment and cochlear hearing impairment.

Based on application, the Middle East & Africa brain implants market is categorized into chronic pain, Parkinson's disease, Alzheimer's disease, epilepsy, essential tremor, depression, dystonia, amyotrophic lateral sclerosis (ALS), and neurofibromatosis 2. The chronic pain segment held 38.3% share of the Middle East & Africa brain implants market in 2022, amassing US$ 87.46 million. It is projected to garner US$ 164.74 million by 2030 to expand at 8.2% CAGR during 2022-2030.

Based on end user, the Middle East & Africa brain implants market is bifurcated into hospitals and specialized clinics/neurological centers. The hospitals segment held 72.1% share of the Middle East & Africa brain implants market in 2022, amassing US$ 164.60 million. It is projected to garner US$ 344.82 million by 2030 to expand at 9.7% CAGR during 2022-2030.

Based on country, the Middle East & Africa brain implants market is categorized into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East and Africa. Saudi Arabia held 40.1% share of Middle East & Africa brain implants market in 2022, amassing US$ 91.60 million. It is projected to garner US$ 177.45 million by 2030 to expand at 8.6% CAGR during 2022-2030.

Key players operating in the Middle East & Africa brain implants market are Abbott Laboratories, Boston Scientific Corp, Medtronic Plc, and Renishaw Plc among others.

• In June 2023; Boston Scientific Corp received US Food and Drug Administration (FDA) approval for the Vercise Neural Navigator 5 Software, which when used as part of the Vercise Genus Deep Brain Stimulation (DBS) Systems. It provides clinicians with simple and actionable data for efficient programming in the treatment of people living with Parkinson's disease or essential tremor.
  
  
  Contact Us
  Phone: +16467917070
  Email Id: sales@businessmarketinsights.com